TetraLogic Pharmaceuticals, Inc.: Series C $5M

Posted in I - Series C, Q - 3Q10, R - NORTH EAST, X - Apoptosis, X - Necrosis, XX - PA

TetraLogic Pharmaceuticals (Malvern, PA) a clinical-stage small molecule company focused on apoptosis and necrosis modulation for potential cancer, cardiovascular, neurological and ophthalmic disease treatment, closed a $5M Series C financing, bringing the total round to $37M. Participants include Pfizer Venture Investments, Clarus Ventures, Hatteras Venture Partners, Amgen Ventures, HealthCare Ventures, Latterell Venture Partners, Novitas Capital, [...]

Aug

2010

TetraLogic Pharmaceuticals, Inc.: Series C $32M

Posted in I - Series C, Q - 3Q10, R - NORTH EAST, X - Apoptosis, X - Necrosis, XX - PA

TetraLogic Pharmaceuticals (Malvern, PA) a preclinical-stage small molecule company focused on apoptosis and necrosis modulation for potential cancer, cardiovascular, neurological and ophthalmic disease treatment, closed a $32M Series C financing. Participants include Clarus Ventures, Hatteras Venture Partners, Amgen Ventures, HealthCare Ventures, Latterell Venture Partners, Novitas Capital, Quaker BioVentures and Vertical Group.

Apr

2010

Gemin X Pharmaceuticals, Inc.: Series D $16M

Posted in I - Series D, Q - 2Q10, R - INTERNATIONAL, X - Apoptosis, X - Oncology

Gemin X Pharmaceuticals (Canada) a clinical-stage biopharmaceutical company developing focused on modulating apoptotic therapeutics for hematological and solid tumors, including chronic lymphocytic leukemia, melanoma, small cell lung cancer, lymphoma, myeloma and glioblastoma multiforme, closed a $16M Series D financing. Participants include Caxton Advantage Life Sciences Fund and Sanderling Ventures.

Nov

2008

Apoptos, Inc.: Series A $28M

Posted in I - Series A, Q - 2Q08, R - WEST, X - Apoptosis, X - Oncology

Apoptos (San Diego, CA) developer of small molecule oncology therapeutics that activate apoptosis, closed a $28M Series B financing. Participants include Venrock, ARCH Venture Partners, OrbiMed Advisors, and Advanced Technology Ventures.

Nov

2008

Apogenix GmbH: Series B $44.0M

Posted in I - Series B, Q - 2Q08, R - INTERNATIONAL, X - Apoptosis

Apogenix (Germany) development-stage biopharmaceutical company focused on targeted modulation of apoptosis, closed a $44M Series B financing. Participants include Dievini Hopp BioTech Holdings.

to top of page...